Overview

Elevate Endocrine Care with Precision Pharmacogenomics

Personalize treatments for diabetes, thyroid disorders, and beyond—reducing complications and boosting patient outcomes across your health system.

Schedule a Demo Contact us

Overview

Hormonal and metabolic disorders require carefully tailored therapies due to the delicate balance of hormones and the potential for varied patient responses. PGxAI's Endocrinology module (PGxHorme™) integrates advanced pharmacogenomics and real-world data to help endocrinologists optimize treatments for diabetes, thyroid dysfunctions, bone health, and more. By aligning each patient's genetic profile with the right medication and dosage, PGxHorme™ reduces adverse effects, improves glycemic control, and enhances long-term quality of life.

•

50+ endocrine therapies covered, including oral hypoglycemics, insulin, thyroid meds, and hormonal supplements.

•

35 critical genetic markers analyzed for drug metabolism and responsiveness.

•

AI-driven insights updated in real time, minimizing trial-and-error and improving clinical outcomes.

Key Highlights

Serving every stakeholder in healthcare

Schedule a Demo Contact Us

Comprehensive Drug-Gene Analysis

Guides selection of Metformin, GLP-1 agonists, thyroid hormones, and other endocrine agents based on each patient's genetic makeup.

Improved Glycemic Control

Personalized dosing strategies reduce hypoglycemic events and optimize A1C levels in diabetic patients.

Reduced Hormonal Imbalances

Genetic markers help tailor therapies for thyroid disorders and hormonal replacement, minimizing overtreatment or undertreatment.

Reimbursement Pathways

Supported by standard CPT codes, making personalized endocrinology both clinically effective and financially sustainable.

Clinical Impact

Maximize Clinical Impact with PGxAI

Schedule a Demo Contact Us

Precision-Guided Therapy Optimization

PGxAI mines genotype, phenotype, and comorbidity data in real time to recommend the optimal drug–dose pair at the first prescription. By accounting for actionable allelic variants and metabolic phenotypes, it minimizes trial-and-error titration and sharply reduces severe drug–gene and drug–drug interactions.

Superior Patient Outcomes & Experience

Genomically informed prescribing lowers adverse-event rates, accelerates therapeutic response, optimizes co-administered medications and boosts adherence. Patients spend less time managing side effects and more time benefiting from treatment, enhancing both clinical endpoints and satisfaction metrics across specialties.

Demonstrable Value-Based Performance

Fewer complications, shorter lengths of stay, and reduced readmissions translate into measurable gains on CMS and private-payer quality dashboards. Institutions leveraging PGxAI can document higher quality scores and capture value-based reimbursement upside while lowering total cost of care.

Seamless Team Integration & Scalability

The platform embeds directly into leading EHRs and e-prescribing systems, delivering concise, guideline-aligned reports that support rapid decision-making for multidisciplinary teams. Standardized APIs and CDS hooks allow effortless expansion from pilot units to enterprise-wide deployment without workflow disruption.

Drug Categories

PGxAI supports a wide range of endocrine therapies

Schedule a Demo Contact Us

Oral Hypoglycemics:

Metformin, Sulfonylureas, DPP-4 Inhibitors (e.g., Sitagliptin)

GLP-1 Agonists:

Liraglutide, Semaglutide

Insulin & Analogues:

Regular Insulin, Insulin Glargine, Lispro

Thyroid Medications:

Levothyroxine, Methimazole, Liothyronine

Bone Health:

Bisphosphonates (Alendronate), Vitamin D, Calcium Supplements. Each recommendation is derived from validated genetic data (e.g., CYP2C9, TSH receptor variants) and real-world clinical outcomes.

Case Study

Riverside Endocrine Center

Schedule a Demo Contact Us

Challenge

High rates of toxic side effects in metastatic breast cancer patients on combination chemotherapy, leading to repeated ED visits.

Solution

PGxHorme™ integrated to identify optimal dosing regimens and recommended alternative agents for genetically at-risk patients.

Results

40% reduction in severe hypoglycemic incidents within 6 months, improved glycemic control, and increased patient satisfaction.

What's next

Ready to Shape the Future of Precision Medicine?

Empower your endocrine teams with data-driven pharmacogenomics that streamline therapy selection, reduce complications, and drive better patient outcomes.

Request a Demo

See how PGxHorme™ can elevate your endocrine workflows.